Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recoflavone - Dong-A ST

Drug Profile

Recoflavone - Dong-A ST

Alternative Names: DA-6034; GLH8NDE

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A Pharmaceutical; Dong-A ST
  • Class Anti-inflammatories; Antiallergics; Benzopyrans; Eye disorder therapies; Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Calcium channel agonists; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes; Gastritis

Highest Development Phases

  • Phase III Gastritis
  • Phase II Dry eyes
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 22 Dec 2020 GL Pharm Tech Corporation plans a phase II trial in Dry eyes in April 2021 (Ophthalmic, Drops) (NCT04679883)
  • 23 Jul 2020 Phase-I development is ongoing in South Korea in Dry eyes (NCT04104997)
  • 18 Feb 2020 GL Pharm Tech completes a phase I trial in Dry eyes (In volunteers) in South Korea (Ophthalmic, Drops) (NCT04104997)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top